ArticleThe Journal of clinical endocrinology and metabolism2021
The Impact of the COVID-19 Pandemic on Self-Reported Outcomes in Patients With Adrenal Insufficiency.
Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Endocrine complications of COVID-19: diabetes, musculoskeletal, thyroid, pituitary, adrenal, and gonadal disorders.Journal of the Endocrine Society · 2026Review
- Adrenal crises and quality of life after bilateral adrenalectomy vs primary autoimmune adrenal insufficiency.Journal of the Endocrine Society · 2026Article
- Cognitive Assessment in Adults With Adrenal Cortisol Insufficiency: Challenges and Opportunities.Endocrine reviews · 2026Review
- Hypopituitarism and COVID-19.Pituitary · 2024Review
- Serological Evidence and Self-reported Outcomes in Patients with Adrenal Insufficiency during the First Waves of COVID-19 in North-East Italy.Endocrine, metabolic & immune disorders drug targets · 2024Article
- COVID-19 pandemic and adrenals: deep insights and implications in patients with glucocorticoid disorders.Endocrine · 2023Review
- Impact of coronavirus disease 2019 on patients with primary adrenal insufficiency: a cross-sectional study.Endocrine connections · 2023Article
- Psychosocial Impact of the COVID-19 Pandemic on Children with Congenital Adrenal Hyperplasia and Their Families.Turkish archives of pediatrics · 2022Article
- The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO International Expert Panel.International journal of molecular sciences · 2022Review
- Quality of Life and its Determinants in Patients With Adrenal Insufficiency: A Survey Study at 3 Centers in the United States.The Journal of clinical endocrinology and metabolism · 2022Article
- COVID-19 and hypopituitarism.Reviews in endocrine & metabolic disorders · 2022Review
- Significant risk of COVID-19 and related-hospitalization among patients with adrenal insufficiency: A large multinational survey.Frontiers in endocrinology · 2022Article
- The Impact of the COVID-19 Pandemic on Self-Reported Outcomes in Patients With Adrenal Insufficiency.The Journal of clinical endocrinology and metabolism · 2021Article
- Frequently Asked Questions in Patients With Adrenal Insufficiency in the Time of COVID-19.Frontiers in endocrinology · 2021Review
- Racial and ethnic differences in distress, discrimination, substance use coping, and nicotine use among parents during COVID-19.Journal of ethnicity in substance abuseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
contextThe COVID-19 pandemic has impacted healthcare environment.
objectiveTo determine the impact of the pandemic on self-reported outcomes in patients with adrenal insufficiency (AI). DESIGN AND
settingProspective longitudinal survey study at 2 tertiary centers.
participantsPatients with AI.
interventionPatient-centered questionnaire.
main outcome measuresDepression Anxiety Stress Scales-21, Short Form-36, and AI self-management.
resultsOf 342 patients, 157 (46%) had primary AI, 109 (32%) had secondary AI, and 76 (22%) had glucocorticoid-induced AI. When compared to prepandemic, daily glucocorticoid dose and number of adrenal crises did not change. However, patients reported a higher financial impact from AI (34% vs 23%, P = 0.006) and difficulty accessing medical care (31% vs 7%, P < 0.0001) during the pandemic. A third of patients reported difficulty managing AI during the pandemic. After adjusting for duration and subtypes of AI, younger patients [odds ratio (OR) 2.3, CI 95% 1.3-4.1], women (OR 3.7, CI 95% 1.9-7.1), poor healthcare access(OR 4.2, CI 95% 2.3-7.7), lack of good insurance support (OR 2.8, CI 95% 1.3-5.9), and those with a higher financial impact (OR 2.3, CI 95% 1.3-4.3) reported greater difficulties managing AI. Patients were more likely to report a higher anxiety score (≥8) if they found managing AI challenging during the pandemic (OR 3.0, CI 95% 1.3-6.9), and had lower Physical Component Summary (OR 4.9, CI 95% 2.2-11.0) and Mental Component Summary (OR 4.1, CI 95% 1.8-9.5) scores prior to the pandemic.
conclusionsA third of patients with AI reported difficulties with management of AI during the pandemic, particularly in younger patients, women, and those with poor healthcare access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.